The present invention relates to: an antibody (particularly a monoclonal antibody), a chimeric antibody, a humanized antibody and a human antibody, which specifically recognize human ±9 integrin; a hybridoma cell which produces the monoclonal antibody; a method for producing the monoclonal antibody; a method for producing the hybridoma cell; a therapeutic agent comprising the anti-human ±9 integrin antibody; a diagnostic agent comprising the human ±9 integrin antibody; a method for screening a compound which inhibits the activity of human ±9 integrin; and the like.